Abstract
We describe a selective and a highly sensitive high-performance liquid chromatography-electron spray ionization-collision induced dissociation-tandem mass spectrometry (HPLC-ESI-CID-MS/MS) assay for the Aurora A kinase inhibitor MLN8237 in human plasma. The intra-day precision based on the standard deviation of replicates of quality control samples ranged from 0.2 to 4% and with accuracy ranging from 96 to 102%. The inter-day precision ranged from 0.5 to 7% and the accuracy ranged from 93 to 105%. Stability studies showed that MLN8237 was stable both during the expected conditions for sample preparation and storage. The lower limit of quantification for MLN8237 was 5. ng/mL. The analytical method showed excellent sensitivity, precision, and accuracy. This method is robust and is being successfully employed in a Children's Oncology Group Phase 1 Consortium study of MLN8237 in children with cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2369-2373 |
| Number of pages | 5 |
| Journal | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences |
| Volume | 878 |
| Issue number | 25 |
| DOIs | |
| State | Published - Sep 2010 |
Bibliographical note
Funding Information:Supported in part by grants to the Children's Oncology Group from the National Cancer Institute ( U01 CA97452 ) and Millennium Pharmaceuticals.
Keywords
- Cancer
- LC-ESI-CID-MS/MS
- MLN8237
- Pediatric
- Plasma
